Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1981 Jan;31(1):391–395. doi: 10.1128/iai.31.1.391-395.1981

Effects of route and time of administration of antiserum on protection of mice from lethal infection due to group B Streptococcus type III.

B F Stanton, R S Baltimore, D G Shedd
PMCID: PMC351796  PMID: 7011999

Abstract

The present study examines a mouse model of infection due to group B Streptococcus serotype III (GBS-III) as to the route and timing of antiserum administration for protection and quantitation of bacteremia with and without antiserum. Data for these parameters are contrasted with those after challenge with serotype Ia of group B Streptococcus (GBS-Ia). An intraperitoneal injection of GBS organisms and protective antiserum from a single syringe can be used to create an animal model of disease. Intraperitoneal injection of GBS-III resulted in bacteremia at 0.5 h both in animals who did not receive antiserum (17.4 X 10(2) +/- 7.6 X 10(2) colony-forming units per ml of blood samples) and in animals who received antiserum (19.3 X 10(1) +/- 6.8 X 10(1) colony-forming units per ml). Although intraperitoneal injection of GBS-Ia also resulted in bacteremia evident by 0.5 h in unprotected animals (30.1 X 10(2) +/- 3.8 X 10(2) colony-forming units per ml), no bacteremia occurred in protected recipients of this organism. Bacteremia due to GBS-Ia and GBS-III logarithmically increased until at least 7 h. Bacteremia due to GBS-III in protected animals was cleared by 24 h. Protection against GBS disease did not require simultaneous or proximate administration of the organism and the antiserum. Mice could be protected from death after intraperitoneal challenge with GBS-III or GBS-Ia by antiserum administered intravenously or intraperitoneally from 6 h before to 2.5 h after challenge.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthony B. F. Immunity to the group B streptococci: interaction of serum and macrophages with types Ia, Ib, and Ic. J Exp Med. 1976 May 1;143(5):1186–1198. doi: 10.1084/jem.143.5.1186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Barrett F. F., Gordon R. C., Yow M. D. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr. 1973 Apr;82(4):724–729. doi: 10.1016/s0022-3476(73)80606-7. [DOI] [PubMed] [Google Scholar]
  3. Baker C. J., Barrett F. F. Transmission of group B streptococci among parturient women and their neonates. J Pediatr. 1973 Dec;83(6):919–925. doi: 10.1016/s0022-3476(73)80524-4. [DOI] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  6. Baltimore R. S., Kasper D. L., Vecchitto J. Mouse protection test for group B Streptococcus type III. J Infect Dis. 1979 Jul;140(1):81–88. doi: 10.1093/infdis/140.1.81. [DOI] [PubMed] [Google Scholar]
  7. Furtado D. Experimental group B streptococcal infections in mice: hematogenous virulence and mucosal colonization. Infect Immun. 1976 May;13(5):1315–1320. doi: 10.1128/iai.13.5.1315-1320.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hemming V. G., Hall R. T., Rhodes P. G., Shigeoka A. O., Hill H. R. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest. 1976 Dec;58(6):1379–1387. doi: 10.1172/JCI108593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mathews J. H., Klesius P. H., Zimmerman R. A. Opsonin system of the group B streptococcus. Infect Immun. 1974 Dec;10(6):1315–1320. doi: 10.1128/iai.10.6.1315-1320.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stewardson-Krieger P. B., Albrandt K., Nevin T., Kretschmer R. R., Gotoff S. P. Perinatal immunity to group B beta-hemolytic streptococcus type Ia. J Infect Dis. 1977 Nov;136(5):649–654. doi: 10.1093/infdis/136.5.649. [DOI] [PubMed] [Google Scholar]
  12. Summary of the workshop on perinatal infections due to group B Streptococcus. J Infect Dis. 1977 Jul;136(1):137–152. doi: 10.1093/infdis/136.1.137. [DOI] [PubMed] [Google Scholar]
  13. Tieffenberg J., Vogel L., Kretschmer R. R., Padnos D., Gotoff S. P. Chicken embryo model for type III group B beta-hemolytic streptococcal septicemia. Infect Immun. 1978 Feb;19(2):481–485. doi: 10.1128/iai.19.2.481-485.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wennerstrom D. E., Schutt R. W. Adult mice as a model for early onset group B streptococcal disease. Infect Immun. 1978 Feb;19(2):741–744. doi: 10.1128/iai.19.2.741-744.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES